top-left-banner

Friday, Apr 25th

Last update05:27:37 PM GMT

TwitterLinkedinYoutubeGoogleFeed

Banner

User1

User2c

User3

You are here: BioMedTech

BioMedTech

BlueGnome IVF technology reigns in Spain

BlueGnome CEO Dr Nick HaanIVI, the Valencian Infertility Institute, is testing technology from Cambridge UK-based genetic solutions company BlueGnome in patients undergoing IVF treatment at clinics in Spain.

Isogenica pushes into Japan

Isogenica CEO, Dr Kevin MatthewsIsogenica, based at the heart of the Cambridge UK BioMedTech cluster, has made a decisive move to open up Japan as a market for its innovative technology for antibody, protein and peptide design.

Cannabis-based medicine in cancer trial

GW Pharmaceuticals Chairman - Geoffrey GuyA Cambridge UK-based medical technology company has started a critical trial of its cannabis-based Sativex® treatment for pain in advanced cancer patients.

HEE innovation clinches £50k award

At the 2012 Fast Forward Awards, left to right: Stuart Thomson, head of innovation, Robert Donald, Intellectual Property manager, both HEE, with Baroness Wilcox, Minister for Intellectual Property.The development of a web-based tool to accelerate and increase knowledge transfer interactions between the NHS and industry has resulted in an award for Health Enterprise East (HEE) worth £50,000.

Big Apple meets biotech in the cloud

One Nucleus CEO Harriet FearNew York technology ace 365force is taking companies in the Cambridge UK biotechnology cluster into the cloud.

Novartis-Vectura COPD boost

Dr Chris Blackwell, chief executive of VecturaA Novartis study using technology from Cambridge-UK based Vectura has shown rapid, sustained improvement in lung function and symptom relief in sufferers of chronic obstructive pulmonary disease (COPD), the companies have announced.

TSB backs Cambridge diagnostics push

Innova-Lightning-LinkInnova Biosciences, the Cambridge UK-based inventor of Lightning-Link® –a world-leading antibody labelling technology – has been awarded a development of prototype grant c£210,000 by the Technology Strategy Board.

GSK pays £61m for Cellzome

Tim Edwards, Cellzome’s CEOGlaxoSmithKline plc (GSK) is buying Cellzome for £61 million cash by hoovering up the shares in the company that it doesn’t already own.

Page 52 of 111